MiNK Therapeutics (NASDAQ:INKT) Price Target Lowered to $4.00 at Robert W. Baird

Posted by Xavier Holt on Nov 16th, 2024

MiNK Therapeutics (NASDAQ:INKT – Free Report) had its price target cut by Robert W. Baird from $8.00 to $4.00 in a report released on Friday,Benzinga reports. They currently have an outperform rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of MiNK Therapeutics in a report on Wednesday, October 9th.

Read Our Latest Report on INKT

MiNK Therapeutics Stock Performance

NASDAQ INKT remained flat at $0.75 during trading hours on Friday. 33,007 shares of the company traded hands, compared to its average volume of 89,830. The stock has a 50-day moving average of $0.73 and a 200-day moving average of $0.85. MiNK Therapeutics has a 52-week low of $0.57 and a 52-week high of $1.90. The company has a market cap of $29.81 million, a P/E ratio of -1.93 and a beta of 0.05.

MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. On average, analysts expect that MiNK Therapeutics will post -0.33 earnings per share for the current year.

Institutional Trading of MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC increased its position in MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) by 21.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 127,841 shares of the company’s stock after buying an additional 22,613 shares during the period. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. 2.87% of the stock is owned by hedge funds and other institutional investors.

About MiNK Therapeutics

(Get Free Report)

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.